| SABS |
SAB Biotherapeutics, Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$14,323,021 |
|
7,125,881 |
|
Woodline Partners LP |
30 Sep 2025 |
| ALGS |
Aligos Therapeutics, Inc. |
Voting Common Stock, par value $0.0001 per share |
8.7% |
$4,588,584 |
-$491,015 |
468,199 |
-9.7% |
Woodline Partners LP |
30 Sep 2025 |
| AIRO |
AIRO Group Holdings, Inc. |
Common Stock, par value $0.000001 per share |
8.5% |
$52,858,886 |
+$15,368,755 |
2,753,067 |
+41% |
Woodline Partners LP |
30 Sep 2025 |
| OM |
Outset Medical, Inc. |
Common Stock, par value $0.001 per share |
7.5% |
$15,392,352 |
|
1,325,784 |
|
Woodline Partners LP |
31 Mar 2025 |
| PLRX |
PLIANT THERAPEUTICS, INC. |
Common Stock, par value $0.0001 per share |
7.3% |
$6,667,129 |
|
4,504,817 |
|
Woodline Partners LP |
30 Sep 2025 |
| ZVRA |
ZEVRA THERAPEUTICS, INC. |
Common Stock, par value $0.0001 per share |
6.2% |
$33,058,120 |
|
3,476,143 |
|
Woodline Partners LP |
30 Sep 2025 |
| EQ |
Equillium, Inc. |
Common Stock, par value $0.0001 per share |
5.9% |
$5,016,841 |
|
3,508,771 |
|
Woodline Partners LP |
30 Sep 2025 |
| TNGX |
Tango Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
5.6% |
$35,757,343 |
|
6,029,906 |
|
Woodline Partners LP |
30 Jun 2025 |
| VSH |
VISHAY INTERTECHNOLOGY INC |
Common Stock, par value $0.10 per share |
5.5% |
$104,250,604 |
|
6,813,765 |
|
Woodline Partners LP |
30 Sep 2025 |
| TNYA |
Tenaya Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
5% |
$6,120,000 |
+$2,097,006 |
9,000,000 |
+52% |
Woodline Partners LP |
30 Jun 2025 |
| SGMT |
Sagimet Biosciences Inc. |
Series A Common Stock, par value $0.0001 per share |
4.8% |
$10,299,309 |
-$7,211,088 |
1,501,357 |
-41% |
Woodline Partners LP |
30 Sep 2025 |
| GRDN |
Guardian Pharmacy Services, Inc. |
Class A Common Stock, par value $0.001 per share |
4.5% |
$10,004,392 |
|
415,120 |
|
Woodline Partners LP |
31 Dec 2024 |
| TARA |
Protara Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
3.9% |
$5,751,035 |
|
1,331,258 |
|
Woodline Partners LP |
31 Dec 2024 |
| TVTX |
Travere Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
2.4% |
$38,750,646 |
|
2,114,056 |
|
Woodline Partners LP |
31 Dec 2024 |